APA (7th ed.) Citation

LE, A., RM, S., DJ, D., & M, S. (2025). Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood cancer journal, 15(1), 192. https://doi.org/10.1038/s41408-025-01406-6

Chicago Style (17th ed.) Citation

LE, Aguirre, Stone RM, DeAngelo DJ, and Stahl M. "Correspondence on: Oral Decitabine Cedazuridine with and Without Venetoclax in Higher-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia: A Propensity Score-matched Study." Blood Cancer Journal 15, no. 1 (2025): 192. https://doi.org/10.1038/s41408-025-01406-6.

MLA (9th ed.) Citation

LE, Aguirre, et al. "Correspondence on: Oral Decitabine Cedazuridine with and Without Venetoclax in Higher-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia: A Propensity Score-matched Study." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 192, https://doi.org/10.1038/s41408-025-01406-6.